Mixed results for AstraZeneca in Scotland while patient access scheme swings yes for Pfizer
This article was originally published in Scrip
Executive Summary
There was mixed news for AstraZeneca in Scotland after the country's health technology appraisal body, the Scottish Medicines Consortium, turned down Seroquel (quetiapine) for major depressive episodes in bipolar disorder but accepted Brillique (ticagrelor)for atherothrombotic events in adult with acute coronary syndromes. Meanwhile, a patient access scheme helped Pfizer secure a yes for its Sutent (sunitinib).
You may also be interested in...
Canada Counters Drug Shortages With Export Bans
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
The COVID-19 Economic Crisis – Fallout And Opportunities
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
Real World Data Failed To Impress Kaftrio’s European Reviewers
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Need a specific report? 1000+ reports available
Buy Reports